|
1
|
Jinushi M: The role of innate immune
signals in antitumor immunity. OncoImmunology. 1:189–194. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baniyash M, Sade-Feldman M and Kanterman
J: Chronic inflammation and cancer: Suppressing the suppressors.
Cancer Immunol Immunother. 63:11–20. 2014. View Article : Google Scholar
|
|
4
|
Zitvogel L, Kepp O, Galluzzi L and Kroemer
G: Inflammasomes in carcinogenesis and anticancer immune responses.
Nat Immunol. 13:343–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clark AG and Vignjevic DM: Modes of cancer
cell invasion and the role of the microenvironment. Curr Opin Cell
Biol. 36:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dinarello CA: Immunological and
inflammatory functions of the interleukin-1 family. Annu Rev
Immunol. 27:519–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Novick D, Kim S, Kaplanski G and Dinarello
CA: Interleukin-18, more than a Th1 cytokine. Semin Immunol.
25:439–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lamkanfi M: Emerging inflammasome effector
mechanisms. Nat Rev Immunol. 11:213–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Apte RN, Dotan S, Elkabets M, White MR,
Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y and Voronov E: The
involvement of IL-1 in tumorigenesis, tumor invasiveness,
metastasis and tumor- host interactions. Cancer Metastasis Rev.
25:387–408. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Apte RN, Krelin Y, Song X, Dotan S, Recih
E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, et al:
Effects of micro-environment- and malignant cell-derived
interleukin-1 in carcinogenesis, tumour invasiveness and
tumour-host interactions. Eur J Cancer. 42:751–759. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A,
Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al:
Expression of interleukin- 1beta in human breast carcinoma. Cancer.
80:421–434. 1997. View Article : Google Scholar
|
|
13
|
Pantschenko AG, Pushkar I, Anderson KH,
Wang Y, Miller LJ, Kurtzman SH, Barrows G and Kreutzer DL: The
interleukin-1 family of cytokines and receptors in human breast
cancer: Implications for tumor progression. Int J Oncol.
23:269–284. 2003.PubMed/NCBI
|
|
14
|
Perrier S, Caldefie-Chézet F and Vasson
MP: IL-1 family in breast cancer: Potential interplay with leptin
and other adipocytokines. FEBS Lett. 583:259–265. 2009. View Article : Google Scholar
|
|
15
|
Iyer SS, Pulskens WP, Sadler JJ, Butter
LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA,
Leemans JC, et al: Necrotic cells trigger a sterile inflammatory
response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA.
106:20388–20393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bergfeld GR and Forrester T: Release of
ATP from human erythrocytes in response to a brief period of
hypoxia and hypercapnia. Cardiovasc Res. 26:40–47. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bodin P and Burnstock G: Purinergic
signalling: ATP release. Neurochem Res. 26:959–969. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vénéreau E, Ceriotti C and Bianchi ME:
DAMPs from cell death to new life. Front Immuno l. 6:4222015.
|
|
19
|
Pellegatti P, Raffaghello L, Bianchi G,
Piccardi F, Pistoia V and Di Virgilio F: Increased level of
extracellular ATP at tumor sites: In vivo imaging with plasma
membrane luciferase. PLoS One. 3:e25992008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schafer R, Sedehizade F, Welte T and
Reiser G: ATP- and UTP-activated P2Y receptors differently regulate
proliferation of human lung epithelial tumor cells. Am J Physiol
Lung Cell Mol Physiol. 285:L376–L385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shabbir M, Ryten M, Thompson C,
Mikhailidis D and Burnstock G: Purinergic receptor-mediated effects
of ATP in high-grade bladder cancer. BJU Int. 101:106–112.
2008.
|
|
22
|
Janssens R and Boeynaems JM: Effects of
extracellular nucleotides and nucleosides on prostate carcinoma
cells. Br J Pharmacol. 132:536–546. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White N, Butler PE and Burnstock G: Human
melanomas express functional P2 X(7) receptors. Cell Tissue Res.
321:411–418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin H, Eun SY, Lee JS, Park SW, Lee JH,
Chang KC and Kim HJ: P2Y2 receptor activation by
nucleotides released from highly metastatic breast cancer cells
increases tumor growth and invasion via crosstalk with endothelial
cells. Breast Cancer Res. 16:R772014. View Article : Google Scholar
|
|
25
|
Joo YN, Jin H, Eun SY, Park SW, Chang KC
and Kim HJ: P2Y2R activation by nucleotides released
from the highly metastatic breast cancer cell MDA-MB-231
contributes to pre- metastatic niche formation by mediating lysyl
oxidase secretion, collagen crosslinking, and monocyte recruitment.
Oncotarget. 5:9322–9334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Clarke M, Collins R, Darby S, Davies C,
Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al:
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG):
Effects of radiotherapy and of differences in the extent of surgery
for early breast cancer on local recurrence and 15-year survival:
An overview of the randomised trials. Lancet. 366:2087–2106. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Veronesi U, Boyle P, Goldhirsch A,
Orecchia R and Viale G: Breast cancer. Lancet. 365:1727–1741. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gebski V, Lagleva M, Keech A, Simes J and
Langlands AO: Survival effects of postmastectomy adjuvant radiation
therapy using biologically equivalent doses: A clinical
perspective. J Natl Cancer Inst. 98:26–38. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ringborg U, Bergqvist D, Brorsson B,
Cavallin-Ståhl E, Ceberg J, Einhorn N, Frödin JE, Järhult J,
Lamnevik G, Lindholm C, et al: The Swedish Council on Technology
Assessment in Health Care (SBU) systematic overview of radiotherapy
for cancer including a prospective survey of radiotherapy practice
in Sweden 2001 - summary and conclusions. Acta Oncol. 42:357–365.
2003. View Article : Google Scholar
|
|
30
|
Delaney G, Jacob S, Featherstone C and
Barton M: The role of radiotherapy in cancer treatment: Estimating
optimal utilization from a review of evidence-based clinical
guidelines. Cancer. 104:1129–1137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fukuda K, Sakakura C, Miyagawa K, Kuriu Y,
Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y,
et al: Differential gene expression profiles of radioresistant
oesophageal cancer cell lines established by continuous
fractionated irradiation. Br J Cancer. 91:1543–1550. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Henness S, Davey MW, Harvie RM, Banyer J,
Wasinger V, Corthals G and Davey RA: Changes in gene expression
associated with stable drug and radiation resistance in small cell
lung cancer cells are similar to those caused by a single X-ray
dose. Radiat Res. 161:495–503. 2004. View
Article : Google Scholar
|
|
33
|
Thomas ED, Clift RA, Hersman J, Sanders
JE, Stewart P, Buckner CD, Fefer A, McGuffin R, Smith JW and Storb
R: Marrow transplantation for acute nonlymphoblastic leukemic in
first remission using fractionated or single-dose irradiation. Int
J Radiat Oncol Biol Phys. 8:817–821. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin H, Ham SA, Kim MY, Woo IS, Kang ES,
Hwang JS, Lee KW, Kim HJ, Roh GS, Lim DS, et al: Activation of
peroxisome proliferator-activated receptor-δ attenuates
glutamate-induced neurotoxicity in HT22 mouse hippocampal cells. J
Neurosci Res. 90:1646–1653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Suganuma M, Okabe S, Marino MW, Sakai A,
Sueoka E and Fujiki H: Essential role of tumor necrosis factor
alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-
deficient mice. Cancer Res. 59:4516–4518. 1999.PubMed/NCBI
|
|
36
|
Egberts JH, Cloosters V, Noack A,
Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C,
Tepel J, et al: Anti-tumor necrosis factor therapy inhibits
pancreatic tumor growth and metastasis. Cancer Res. 68:1443–1450.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schroder K and Tschopp J: The
inflammasomes. Cell. 140:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fink SL and Cookson BT: Apoptosis,
pyroptosis, and necrosis: Mechanistic description of dead and dying
eukaryotic cells. Infect Immun. 73:1907–1916. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Radisky ES and Radisky DC: Matrix
metalloproteinase-induced epithelial-mesenchymal transition in
breast cancer. J Mammary Gland Biol Neoplasia. 15:201–212. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Carlson RW and McCormick B: Update: NCCN
breast cancer clinical practice guidelines. J Natl Compr Canc Netw.
3(Suppl 1): S7–S11. 2005.PubMed/NCBI
|
|
41
|
Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY,
Kim CH, Park HG, Han SI and Kang HS: Induction of metastasis,
cancer stem cell phenotype, and oncogenic metabolism in cancer
cells by ionizing radiation. Mol Cancer. 16:102017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
von Essen CF: Radiation enhancement of
metastasis: A review. Clin Exp Metastasis. 9:77–104. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ko YS, Jin H, Joo Y, Lee JS, Park SW,
Chang KC, Kang KM, Jeong BK and Kim HJ: Radio-resistant breast
cancer cells derived from highly metastatic breast cancer cells
exhibit increased resistance to chemotherapy, enhanced invasive
properties and premetastatic niche formation due to cancer stem
cells. Oncol Rep. In press.
|
|
44
|
Allen IC, TeKippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3
inflammasome functions as a negative regulator of tumorigenesis
during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dupaul-Chicoine J, Yeretssian G, Doiron K,
Bergstrom KS, McIntire CR, LeBlanc PM, Meunier C, Turbide C, Gros
P, Beauchemin N, et al: Control of intestinal homeostasis, colitis,
and colitis-associated colorectal cancer by the inflammatory
caspases. Immunity. 32:367–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chow MT, Sceneay J, Paget C, Wong CS,
Duret H, Tschopp J, Möller A and Smyth MJ: NLRP3 suppresses NK
cell-mediated responses to carcinogen-induced tumors and
metastases. Cancer Res. 72:5721–5732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bhagat Tu, Cui GS, Takaishi G, Kurt-Jones
S, Rickman EA, Betz B, Penz-Oesterreicher KS, Bjorkdahl M, Fox OJG,
et al: Overexpression of interleukin-1beta induces gastric
inflammation and cancer and mobilizes myeloid-derived suppressor
cells in mice. Cancer Cell. 14:408–419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu W, Luo Y, Dunn JH, Norris DA,
Dinarello CA and Fujita M: Dual role of apoptosis-associated
speck-like protein containing a CARD (ASC) in tumorigenesis of
human melanoma. J Invest Dermatol. 133:518–527. 2013. View Article : Google Scholar
|
|
49
|
Kolb R, Phan L, Borcherding N, Liu Y, Yuan
F, Janowski AM, Xie Q, Markan KR, Li W, Potthoff MJ, et al:
Obesity-associated NLRC4 inflammasome activation drives breast
cancer progression. Nat Commun. 7:130072016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Corriden R and Insel PA: Basal release of
ATP: An autocrine- paracrine mechanism for cell regulation. Sci
Signal. 3. pp. re12010, View Article : Google Scholar
|
|
51
|
Lazarowski E: Regulated release of
nucleotides and UDP sugars from astrocytoma cells. Novartis Found
Symp. 276:73–84; discussion 84–90, 107–112, 275–281.
2006.PubMed/NCBI
|
|
52
|
Jacobson KA, Ivanov AA, de Castro S,
Harden TK and Ko H: Development of selective agonists and
antagonists of P2Y receptors. Purinergic Signal. 5:75–89. 2009.
View Article : Google Scholar :
|
|
53
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-beta. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takeuchi O and Akira S: Pattern
recognition receptors and inflammation. Cell. 140:805–820. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Brough D and Rothwell NJ:
Caspase-1-dependent processing of pro-interleukin-1beta is
cytosolic and precedes cell death. J Cell Sci. 120:772–781. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Korcok J, Raimundo LN, Ke HZ, Sims SM and
Dixon SJ: Extracellular nucleotides act through P2X7 receptors to
activate NF-kappaB in osteoclasts. J Bone Miner Res. 19:642–651.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ferrari D, Wesselborg S, Bauer MK and
Schulze-Osthoff K: Extracellular ATP activates transcription factor
NF-kappaB through the P2Z purinoreceptor by selectively targeting
NF-kappaB p65. J Cell Biol. 139:1635–1643. 1997. View Article : Google Scholar
|
|
58
|
Wilden PA, Agazie YM, Kaufman R and
Halenda SP: ATP-stimulated smooth muscle cell proliferation
requires independent ERK and PI3K signaling pathways. Am J Physiol.
275:H1209–H1215. 1998.PubMed/NCBI
|
|
59
|
Baron L, Gombault A, Fanny M, Villeret B,
Savigny F, Guillou N, Panek C, Le Bert M, Lagente V, Rassendren F,
et al: The NLRP3 inflammasome is activated by nanoparticles through
ATP, ADP and adenosine. Cell Death Dis. 6:e16292015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ouyang X, Ghani A, Malik A, Wilder T,
Colegio OR, Flavell RA, Cronstein BN and Mehal WZ: Adenosine is
required for sustained inflammasome activation via the
A2A receptor and the HIF-1α pathway. Nat Commun.
4:29092013. View Article : Google Scholar
|
|
61
|
Yin Y, Cai J, Meng F, Sui C and Jiang Y:
MiR-144 suppresses proliferation, invasion, and migration of breast
cancer cells through inhibiting CEP55. Cancer Biol Ther.
19:306–315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pan Y, Zhang J, Fu H and Shen L: miR-144
functions as a tumor suppressor in breast cancer through inhibiting
ZEB1/2-mediated epithelial mesenchymal transition process.
OncoTargets Ther. 9:6247–6255. 2016. View Article : Google Scholar
|
|
63
|
Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang
Z, Qiu L and Jia X: MicroRNA-144 affects radiotherapy sensitivity
by promoting proliferation, migration and invasion of breast cancer
cells. Oncol Rep. 34:1845–1852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hunter KW, Crawford NP and Alsarraj J:
Mechanisms of metastasis. Breast Cancer Res. 10(Suppl 1): S22008.
View Article : Google Scholar :
|
|
65
|
Talmadge JE and Fidler IJ: AACR centennial
series: the biology of cancer metastasis: historical perspective.
Cancer Res. 70:5649–5669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yokoo T and Kitamura M: Dual regulation of
IL-1 beta-mediated matrix metalloproteinase-9 expression in
mesangial cells by NF-kappa B and AP-1. Am J Physiol.
270:F123–F130. 1996.PubMed/NCBI
|
|
67
|
Ruhul Amin AR, Senga T, Oo ML, Thant AA
and Hamaguchi M: Secretion of matrix metalloproteinase-9 by the
proinflammatory cytokine, IL-1beta: A role for the dual signalling
pathways, Akt and Erk. Genes Cells. 8:515–523. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
Outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825.29–36. 2012.
|
|
69
|
Ren F, Tang R, Zhang X, Madushi WM, Luo D,
Dang Y, Li Z, Wei K and Chen G: Overexpression of MMP family
members functions as prognostic biomarker for breast cancer
patients: A systematic review and meta-analysis. PLoS One.
10:e01355442015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang W, Petrovic JM, Callaghan D, Jones
A, Cui H, Howlett C and Stanimirovic D: Evidence that
hypoxia-inducible factor-1 (HIF-1) mediates transcriptional
activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J
Neuroimmunol. 174:63–73. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jung YJ, Isaacs JS, Lee S, Trepel J and
Neckers L: IL-1beta- mediated up-regulation of HIF-1alpha via an
NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between
inflammation and oncogenesis. FASEB J. 17:2115–2117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Semenza GL: Molecular mechanisms mediating
metastasis of hypoxic breast cancer cells. Trends Mol Med.
18:534–543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Semenza GL: Surviving ischemia: Adaptive
responses mediated by hypoxia-inducible factor 1. J Clin Invest.
106:809–812. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Semenza GL: HIF-1 and tumor progression:
pathophysiology and therapeutics. Trends Mol Med. 8(Suppl 4):
S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
|
